gonadotropins plus GnRH antagonists

PreclinicalSmall molecule

gonadotropins plus GnRH antagonists is one of 7 small molecule programs targeting Ovarian Stimulation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian StimulationCompleted

Ovarian StimulationPreclinical

Completed

Competition

Competitive Landscape

10 competitors in Ovarian Stimulation

#DrugCompanyPhaseTrials

Luveris

Merck & Co.

Phase 3

3 2

Progestin

WWashington University School of Medicine

Phase 3

1 3

Depo-Provera

Eli Lilly

Preclinical

1 4

Gynorest

SSolvay Pharmaceuticals

Preclinical

3 5

Trelstar

OOncoVerity, Inc.

Preclinical

1 6

gonadotropins plus GnRH antagonists

FFundacion Dexeus

Preclinical

1 7

Gonadotropin Releasing Hormone Antagonist

AAssiut University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ovarian Stimulation1 trial

Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation

Completed·FFundacion Dexeus·N/A·NCT01645241·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for gonadotropins plus GnRH antagonists. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gonadotropins plus GnRH antagonists compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gonadotropins plus GnRH antagonists. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fundacion Dexeus company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFundacion Dexeus

gonadotropins plus GnRH antagonists

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ovarian Stimulation1 trial

References

Drug Info

Quick Facts

Related News